Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
Crossref DOI link: https://doi.org/10.1186/s40880-016-0101-7
Published Online: 2016-04-25
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chen, Xue-Lian
Du, Feng
Hong, Ruo-Xi
Wang, Jia-Yu
Luo, Yang
Li, Qing
Fan, Ying
Xu, Bing-He